Seroprevalence of *Toxoplasma gondii* infection among babies in Jeddah Province, Saudi Arabia: a retrospective study

Raafat Abdel Moneim Hassanein, Adel Galal El-Shemi, Mohammed Othman Alkurbi, Ameer Ahmed Alahmadi, Waslallah Saad Almatery

Corresponding author: Adel Galal El-Shemi, Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Mecca, Saudi Arabia. agshemi@uqu.edu.sa

Received: 18 Dec 2021 - Accepted: 02 May 2022 - Published: 26 May 2022

Keywords: *Toxoplasma gondii*, Saudi babies, seroprevalence

Copyright: Raafat Abdel Moneim Hassanein et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Raafat Abdel Moneim Hassanein et al. Seroprevalence of *Toxoplasma gondii* infection among babies in Jeddah Province, Saudi Arabia: a retrospective study. Pan African Medical Journal. 2022;42(72). 10.11604/pamj.2022.42.72.32877

Available online at: https://www.panafrican-med-journal.com/content/article/42/72/full

Seroprevalence of *Toxoplasma gondii* infection among babies in Jeddah Province, Saudi Arabia: a retrospective study

Raafat Abdel Moneim Hassanein\textsuperscript{1,2}, Adel Galal El-Shemi\textsuperscript{1,8}, Mohammed Othman Alkurbi\textsuperscript{1}, Ameer Ahmed Alahmadi\textsuperscript{1}, Waslallah Saad Almatery\textsuperscript{1,3}

\textsuperscript{1}Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Mecca, Saudi Arabia, \textsuperscript{2}Department of Zoonoses, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt, \textsuperscript{3}King Fahad Hospital, Jeddah, Saudi Arabia

\textsuperscript{8}Corresponding author
Adel Galal El-Shemi, Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Mecca, Saudi Arabia
Abstract

Introduction: toxoplasmosis is an opportunistic protozoan disease caused by Toxoplasma gondii (T. gondii) infection. It affects all human ages, including children, and can pose serious health problems, particularly in developing countries. Nevertheless, the epidemiological status of neonatal and childhood toxoplasmosis remains largely unknown in Saudi Arabia. The present study aimed to determine the seroprevalence of T. gondii infection among Saudi babies residing in Jeddah Region of Saudi Arabia. Methods: this hospital-based retrospective study was conducted between January 2019 and March 2021 at three governmental hospitals in Jeddah Region: King Fahad, King Abdulaziz, and East Jeddah Hospital. It included 502 babies (269 boys and 233 girls; 0-4 years old), who were screened by enzyme linked immunosorbent assay (ELISA) for the detection of anti-T. gondii immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies in their serum. Results: among the 502 studied babies, the overall seropositivity rate of T. gondii infection was 18.53% (93/502) subscribed as 90 babies (17.9%) with IgG seropositive and 3 babies (0.60%) with IgM seropositivity. The all IgG seropositive babies were IgM seronegative and vice versa. Additionally, the highest proportion of IgG seropositivity was detected in 0-6 month old babies (7.17%); followed by 5.38% and 4.98% in 7-12 and 13-18 months old babies, respectively, while the 3 babies with IgM seropositivity were 13-18 months old. Conclusion: the present findings highlighted the seroprevalence situation of toxoplasma infection among babies in some Saudi communities and raise the importance to increase the screening programs and preventative implements against toxoplasmosis in Saudi Arabia.

Introduction

Toxoplasmosis is a globally widespread protozoan zoonotic disease caused by infection with T. gondii. The disease represents a major public health threat, and can affect all human ages, particularly in developing countries [1,2]. Approximately one-third of the world human population has chronic toxoplasmosis, and 30% to 50% of its overall endemicity is localized in the Middle East countries [1-3]. The life cycle of T. gondii includes a sexual stage arising in the primary host (i.e, domestic and wild cats), and asexual stage that occurs in the secondary hosts of humans and warm-blooded animals. Each cat can excrete over 20 million oocysts of T. gondii within 4-13 days post-infection; and these oocysts survive in the environment for long period [4,5]. Ingestion of oocysts shed by cats into the environment-and ingestion of raw meat, non-boiled milk, and undercooked food products of infected farm animals, as well drinking of water containing T. gondii cysts, are the main horizontal routes of transmission of human toxoplasmosis [5-7]. Transmission of T. gondii through blood transfusion and organ transfer should not be neglected [8].

At the same time, infection with T. gondii during pregnancy can induce spontaneous abortion and it may be vertically transmitted to fetus; resulting in congenital toxoplasmosis [9]. The incidence and clinical severity of congenital toxoplasmosis is influenced by the stage of pregnancy, the strength of mother and fetus immune response, and the fetal environment characteristics [1,10]. Variable clinical signs have been observed in infants born with congenital toxoplasmosis including ocular damage (retinochoroiditis and blindness), hydrocephalus, macro or microcephalus, cerebral calcifications, delayed neuropsychomotor development and mental retardation [10,11]. Moreover, the European multicenter studies have previously demonstrated that treatment of toxoplasmosis in infected pregnant women does not significantly prevent the risk of its vertical transmission to fetuses [12,13]. Most importantly, in children born with asymptomatic congenital toxoplasmosis, a reactivation or relapse form of the disease, with life-threatening sequences, has been significantly reported during their neonatal to childhood life, or even in their puberty life [14-17].
The less effectiveness of health education practices in preventing the incidence of *T. gondii* infection [18,19], besides the unavailability of vaccine, may increase the impacts of toxoplasmosis on all human ages. Thus, establishment of maternal and neonatal screening programs for toxoplasmosis is an essential demand to improve the child health, particularly when coupled with an effective early treatment [19-21]. Toward this goal, the present study was conducted to highlight the seroprevalence proportion of *T. gondii* infection among a population of Saudi babies living in Jeddah Province in the Western Region of Saudi Arabia.

**Methods**

**Study design, setting and participants:** the present study is a hospital-based retrospective study that was carried out to evaluate the seroprevalence rate of *T. gondii* infection among a population of Saudi babies living in Jeddah Province in the Western Region of Saudi Arabia. In this study, the medical records of a total of 502 Saudi babies (0-4 years old; 269 boys and 233 girls), who were subjected to healthcare check-up and clinical monitoring for infectious diseases at three governmental hospitals in Jeddah Region: King Fahad, King Abdulaziz, and East Jeddah Hospital, between January 2019 and March 2021, were analyzed. Ethical approval for this study was obtained from the Institutional Review Board of the Ministry of Health, Directorate of Health Affairs-Jeddah, Kingdom of Saudi Arabia (ethical approval number: 1461). The minimal study sample size was estimated according to the previously published worldwide reports. Jeddah is the largest city in the Western Region of Saudi Arabia with high population densities and a unique situation on the Red Sea coast, and the above three hospitals were selected in order to maximize the variety of our study sample as they are the main clinical, teaching and training healthcare medical services in Jeddah.

**Data sources/measurement:** the hospital-based serological screening for *T. gondii* infection was carried out by ELISA-based estimation of the specific anti-*T. gondii* IgG and IgM antibodies in serum samples using commercial ENZYWELL TOXOPLASMA IgG and IgM Kit (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) [22,23]. According the manufacturer’s instructions, samples with absorbance higher than the cut-off value (i.e. >1.3 for IgG and >1.2 for IgM) were considered as seropositive, while those with absorbance of <0.7 for IgG and <0.8 for IgM were considered as seronegative. Samples with borderline values (0.7-1.3 for IgG and 0.8-1.2 for IgM) were considered as doubtful (equivocal) results and repeated 2-3 weeks later to be verified as positive or negative [22,23].

**Statistical analysis:** data entry and analysis were done using SPSS software package version 20.0 (SPSS Inc. Chicago, Illinois, USA). The Chi-square ($\chi^2$) test and student “t” test or Mann-Whitney test were used for the categorical data and continuous variables as appropriate. A P-value of <0.05 was considered statistically significant.

**Results**

A total of 93 (18.53%) babies, among the studied 502 babies, were detected to have *T. gondii* infection sub-divided as follow: 17.93% (90/502) were identified as seropositive for anti-*T. gondii* IgG antibodies (i.e. IgG+), and 0.60% (3/502) were identified as seropositive for anti-*T. gondii* IgM antibodies (i.e. IgM+) (Table 1). Additionally, the all babies presented IgG seropositivity were IgM seronegative and vice versa; babies who had IgM seropositivity were IgG seronegative (Table 1). According to the babies’ sex (Table 2), out of the 90 babies who had IgG seropositivity, 49 (54.44%) were boys and 41 (45.56%) were girls, while the 3 babies who had IgM seropositivity were 2 boys and one girl (Table 2).

Next, to try to figure out possible role of baby’s age on the seroprevalence rate of toxoplasmosis (Table 3), we found that the highest proportion of
IgG seropositivity (7.17%) was in 0 to 6 months old babies; followed by a proportion of 5.38%, 4.98% and 0.4% in babies with age of 7-12 months, 13-18 months, and 19-24 months old, respectively. No IgG seropositivity was detected in other age sets. On the other hand, the all 3 babies presented IgM seropositivity (3/502; 0.6%) were with age of 13-18 months old (Table 3). Lastly, no-specific toxoplasmosis clinical sequelae were detected in the medical records of all studied babies.

**Discussion**

Infection with *T. gondii* is one of the most prevalent parasitic zoonotic diseases affecting all human ages worldwide. However, there are scarce evidence concerning the status of relevant of gestational (maternal)/congenital, postnatal and childhood toxoplasmosis in Saudi Arabia [24]. The present hospital-based retrospective study was therefore, undertaken to determine the seroprevalence rates of *T. gondii* infection in a sample population of male and female Saudi national babies residing in Jeddah Province in the Western Region of Saudi Arabia. The study was conducted between January 2019 and March 2021 at three governmental hospitals in Jeddah Region. The age of the study babies ranged from 0 to 4 years old, and the sero-screening procedures of *T. gondii* infection was based on detection of the specific anti-*T. gondii* IgM and IgG antibodies by ELISA [22-25]. The results showed that among the studied 502 babies, 93 (18.53%) babies were detected to have *T. gondii* infection in form of 17.93% and 0.60% positive to anti-*T. gondii* IgG and IgM antibodies, respectively. Additionally, all babies who had IgG+ were IgM-, and vice versa; all babies with IgM seropositivity were IgG seronegative. It is generally recognized that the detection of anti-*T. gondii* IgM antibodies denotes an acute phase of the disease, while the detection of anti-*T. gondii* IgG antibodies indicates a state of chronic infection [22-25]. However, anti-toxoplasma IgG antibodies may be also transmitted passively from the mothers to their newborns and are not endogenously created antibodies [26].

In harmony with our findings, Al-Yami et al. [24] have recently detected the presence of 21.0% and 0.8% seropositivity for anti-*T. gondii* IgG or IgM antibodies, respectively, in 500 paired samples from maternal and newborn (cord blood samples) during child delivery in the Eastern Province of Saudi Arabia [24]. Additionally, data of previous reports concerning the prevalence of toxoplasmosis among the “adult individuals” from different regions in Saudi Arabia have been reviewed and revealed that the seroprevalence of anti-toxoplasma IgG (+) antibodies ranged from 9.13% in the Hail Region to 39.43% in the Eastern Region, while the seroprevalence of its specific IgM (+) antibodies ranged from 0.44% in the northern region to 17.7% in the eastern region of Saudi Arabia [27]. Most interestingly, our current findings are also in consistency with those of some worldwide studies. For instance, the weighed prevalence of IgM+/symptomatic *T. gondii* infection has been estimated as 0.396% to 0.835% among the Mexican newborns and children during 1954 to 2009 [28]. Furthermore, Danish Congenital Toxoplasmosis Study Group (Denmark) has previously disclosed that a neonatal serological screening program for 12 months post-delivery and based on detection of IgM antibodies alone can effectively recognize 70%-80% of cases of congenital toxoplasmosis [29].

Changes in environmental and climate conditions, differences in host susceptibility; hygiene facilities and other socioeconomic conditions, and complexity pattern of *T. gondii* transmission and variability in its diagnostic methods, inevitably lead to distinct variations in the seroprevalence rates of positive *T. gondii* infection at the global, regional, and country levels, and even between the different regions of a country [30,31]. In a constant line, though its influence is not determined yet in children, several reports have suggested the central role of age in the variation of toxoplasmosis prevalence among adult individuals [1,2,27]. We herein observed that the
highest proportion of IgG seropositivity was in 0 to 6 months old babies; followed by those with age of 7-12 months and 13-18 months and the all three cases of IgM seropositivity were reported in babies with age of 13-18 months old. Our findings are nearly in matching with those reported previously in Poland [32]. The explanatory reasons beyond these findings are not well known; however, it may attribute to one or more of the following probabilities: passive transmission of anti-\textit{T. gondii} IgG antibodies from chronically infected mothers [26]; vertical transmission of \textit{T. gondii} during pregnancy/labor [33]; or an exposure to sources of \textit{T. gondii} infection during/post-labor process. At that regard, a previous report from Brazil indicated that from 487 infected pregnant mothers, 7 newborns (1.42%) were confirmed to have vertically transmitted acute \textit{T. gondii} infection [34]. These collective data argue for deeper investigations to explore the potential risk factors that threat the prevalence of toxoplasmosis during the neonatal and childhood life.

**Limitations:** in addition to the study's main findings, important limitations were inevitably identified, that should be addressed in the future. First, in IgM (+) babies there are difficulties in defining the source of these anti-\textit{T. gondii} IgM antibodies if they were a result of a vertically transmitted, neonatal, postnatal acquired \textit{T. gondii} infection, or due to a reactivation of a latent congenital infection [15]. Thus, it was had to add a second level of assessments such as IgG avidity test, immunoblotting test, or polymerase chain reaction (PCR) detection of \textit{T. gondii} (DNA) to identify the time/source of the infection [35]. Second, there is also a conflict in defining the source of anti-\textit{T. gondii} IgG antibodies in their seropositive babies if they were secondary to congenital or postnatal \textit{T. gondii} infection, or they were transmitted passively from the immunized mothers to their newborns and did not represent endogenously created antibodies [26]. Third, there is a notable lack in the information related to variables that might had an influence on the seroprevalence of \textit{T. gondii} infection among the studied babies; such as immune status of the babies, maternal toxoplasmosis screening data, and type of labor (normal or cesarean). Fourth, the present data were drawn from limited samples of Saudi babies resident in the Western Region of Saudi Arabia that in turn may not necessarily have represented the overall national seroprevalence rate of toxoplasmosis. Coherently, further large scale and multi-centers prospective screening and follow-up studies are essentially required; in which a second level of the above mentioned examinations will be added. The same can be also said for pregnant women to prevent the risk of vertically transmitted congenital toxoplasmosis.

**Conclusion**

Findings of the present study showed that there was 17.93% and 0.6% seropositivity prevalence for anti-\textit{T. gondii} IgG and IgM antibodies, respectively, among the 502 studied babies, who were resident in Jeddah Province of Saudi Arabia between January 2019 and March 2021. These findings can in turn raise a dire need to increase the screening implements and improve the preventative programs against \textit{T. gondii} infection in the Kingdom of Saudi Arabia.

**What is known about this topic**
- There is scarce evidence in the literature related to the incidence of congenital, neonatal and childhood toxoplasmosis in Saudi Arabia;
- The neonatal and childhood screening program for toxoplasma disease in Saudi Arabia remains challenging.

**What this study adds**
- The present findings of the current study provide an insight into the prevalence of toxoplasmosis among babies in the Kingdom of Saudi Arabia;
- The present findings can also serve as a starting point for increasing the neonatal and childhood screening policies and preventative programs against \textit{T. gondii} infection in the Kingdom of Saudi Arabia.
Competing interests

The authors declare no competing interest.

Authors' contributions

All authors coordinated in the preparation of data, participated in the preparation and writing of the manuscript. They also read and agreed to the final manuscript.

Tables

Table 1: the overall seroprevalence of anti-*T. gondii* IgG and IgM antibodies in the studied babies

Table 2: prevalence of anti-*T. gondii* IgG and IgM antibodies seropositivity according to the sex of the studied babies

Table 3: prevalence of anti-*T. gondii* IgG and IgM antibodies seropositivity according to the ages of the studied babies

References

1. Rojas-Pirela M, Medina L, Rojas MV, Liempi AI, Castillo C, Pérez-Pérez E *et al.* Congenital transmission of apicomplexan parasites: a review. Front Microbiol. 2021;12: 751648. PubMed | Google Scholar

2. Milne G, Webster JP, Walker M. Toward improving interventions against toxoplasmosis by identifying routes of transmission using sporozoite-specific serological tools. Clin Infect Dis. 2020;71(10): e686-e693. PubMed | Google Scholar

3. Alzaheb RA. Seroprevalence of Toxoplasma gondii and its associated risk factors among women of reproductive age in Saudi Arabia: a systematic review and meta-analysis. Int J Womens Health. 2018;10: 537-544. PubMed | Google Scholar

4. Dubey JP. Oocyst shedding by cats fed isolated bradyzoites and comparison of infectivity of bradyzoites of the VEG strain *Toxoplasma gondii* to cats and mice. J Parasitol. 2001;87(1): 215-9. PubMed | Google Scholar

5. Hussain MA, Stitt V, Szabo EA, Nelan B. Toxoplasma gondii in the food supply. Pathogens. 2017;6(2): 21. PubMed | Google Scholar

6. Cenci-Goga BT, Rossitto PV, Sechi P, McCrindle CME, Cullorm JS. Toxoplasma in animals, food, and humans: an old parasite of new concern. Foodborne Pathog Dis. 2011;8(7): 751-762. PubMed | Google Scholar

7. Guo M, Dubey JP, Hill D, Buchanan RL, Gamble HR, Jones JL *et al.* Prevalence and risk factors for *Toxoplasma gondii* infection in meat animals and meat products destined for human consumption. J Food Prot. 2015;78(2): 457-476. PubMed | Google Scholar

8. Karimi G, Mardni A, Zadsar M. Toxoplasma and blood transfusion. Iran J Parasitol. 2014;9(4): 597-598. PubMed | Google Scholar

9. Gómez-Chávez F, Cañedo-Solares I, Ortiz-Alegria LB, Flores-García Y, Luna-Pastén H, Figueroa-Damián R *et al.* Maternal immune response during pregnancy and vertical transmission in human toxoplasmosis. Front Immunol. 2019;10: 285. PubMed | Google Scholar

10. McAuley JB. Congenital toxoplasmosis. J Pediatric Infect Dis Soc. 2014;3 Suppl 1 (Suppl 1): S30-5. PubMed | Google Scholar

11. Olariu TR, Remington JS, McLeod R, Alam A, Montoya JG. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J. 2011;30(12): 1056-61. PubMed | Google Scholar

12. Gilbert R, Gras L, European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of *Toxoplasma gondii*. BJOG. 2003;110(2): 112-20. PubMed | Google Scholar
13. Gras L, Wallon M, Pollak A, Cortina-Borja M, Evengard B, Hayde M et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr. 2005;94(12): 1721-31. PubMed | Google Scholar

14. Koppe JG, Loewer-Sieger D H, de Roever-Bonnet H. Results of a 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1(8475): 254-6. PubMed | Google Scholar

15. Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol. 2013;114: 125-45. PubMed

16. Pizzi HL, Maffrand R, Pizzi DR, Páez Rearte MG, Fernández GL. Toxoplasmic retinochoroiditis reactivated in the puberty. Rev Fac Cien Med Univ Nac Cordoba. 2000;57(2): 249-51. PubMed | Google Scholar

17. Wang ZD, Liu HH, Ma ZX, Ma HY, Li ZY, Yang ZB et al. Toxoplasma gondii Infection in immunocompromised patients: a systematic review and meta-analysis. Front Microbiol. 2017;8: 389. PubMed | Google Scholar

18. Foulon W, Naessens A, Ho-Yen D. Prevention of congenital toxoplasmosis. J Perinat Med. 2000;28(5): 337-45. PubMed | Google Scholar

19. Schmidt DR, Hogh B, Andersen O, Fuchs J, Fledelius H, Petersen E. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. Arch Dis Child. 2006;91(8): 661-5. PubMed | Google Scholar

20. Gilbert R, Dezateux C. Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established. Arch Dis Child. 2006;91(8): 629-632. PubMed | Google Scholar

21. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. 1994;330(26): 1858-63. PubMed | Google Scholar

22. Alghamdi J, Elamin MH, Alhabib S. Prevalence and genotyping of Toxoplasma gondii among Saudi pregnant women in Saudi Arabia. Saudi Pharm J. 2016;24(6): 645-651. PubMed | Google Scholar

23. Fenta DA. Seroprevalence of Toxoplasma gondii among pregnant women attending antenatal clinics at Hawassa University comprehensive specialized and Yirgalem General Hospitals, in Southern Ethiopia. BMC Infect Dis. 2019;19(1): 1056. PubMed | Google Scholar

24. Al-Yami FS, Dar FK, Yousef AI, Al-Qurouni BH, Al-Jamea LH, Rabaan AA et al. A pilot study on screening for gestational/congenital toxoplasmosis of pregnant women at delivery in the Eastern Province of Saudi Arabia. Saudi Pharm J. 2021;29(4): 343-350. PubMed | Google Scholar

25. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002;8(10): 634-640. PubMed | Google Scholar

26. Diesel AA, Zachia SA, Müller ALL, Perez AV, Uberti FAF, Magalhães JAA. Follow-up of Toxoplasmosis during pregnancy: ten-year experience in a university hospital in Southern Brazil. Rev Bras Ginecol Obstet. 2019;41(9): 539-547. PubMed | Google Scholar

27. Mohamed K. Toxoplasmosis in humans and animals in Saudi Arabia: a systematic review. J Infect Dev Ctries. 2020;14(8): 800-811. PubMed | Google Scholar

28. Galvan-Ramirez Mde L, Troyo-Sanroman R, Roman S, Bernal-Redondo R, Vázquez Castellanos JL. Prevalence of toxoplasmosis infection in Mexican newborns and children: a systematic review from 1954 to 2009. ISRN Pediatr. 2012;2012: 501216. PubMed | Google Scholar

29. Lebech M, Andersen O, Christensen NC, Hertel J, Nielsen HE, Peitersen B et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group. Lancet. 1999;353(9167): 1834-7. PubMed | Google Scholar
30. Yan C, Liang LJ, Zheng KY, Zhu XQ. Impact of environmental factors on the emergence, transmission and distribution of Toxoplasma gondii. Parasit Vectors. 2016;9: 137. PubMed | Google Scholar

31. Bigna JJ, Tochie JN, Tounouga DN, Bekolo AO, Ymele NS, Youda EL et al. Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: a systematic review, modelling and meta-analysis. Sci Rep. 2020;10(1): 12102. PubMed | Google Scholar

32. Niemiec KT, Raczyński P, Markiewicz K, Leibschang J, Ceran A. The prevalence of Toxoplasma gondii infection among 2016 pregnant women and their children in the Institute of Mother and Child in Warsaw. Wiad Parazytol. 2002;48(3): 293-9. PubMed | Google Scholar

33. Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human toxoplasmosis: a systematic review. Pathog Glob Health. 2017;111(7): 333-342. PubMed | Google Scholar

34. Gontijo da Silva M, Clare Vinaud M, de Castro AM. Prevalence of toxoplasmosis in pregnant women and vertical transmission of Toxoplasma gondii in patients from basic units of health from Gurupi, Tocantins, Brazil, from 2012 to 2014. PLoS One. 2015;10(11): e0141700. PubMed | Google Scholar

35. Laboudi M. Review of toxoplasmosis in Morocco: seroprevalence and risk factors for toxoplasma infection among pregnant women and HIV-infected patients. The Pan African Medical Journal. 2017;27: 269. PubMed | Google Scholar

Table 1: the overall seroprevalence of anti-T. gondii IgG and IgM antibodies in the studied babies

|               | IgG+ no (%) | IgM+ no (%) | IgG+/ IgM- no (%) | IgG-/ IgM+ no (%) | IgG+/ IgM+ no (%) |
|---------------|-------------|-------------|------------------|------------------|------------------|
| Presented     | 90/502 (17.93) | 3/502 (0.60) | 90/502 (17.93) | 3/502 (0.60) | 0/502 (0.0) |
| Not-presented | 412/502 (82.1)* | 499/502 (99.4)* | 412/502 (82.1)* | 499/502 (99.4)* | 502/502 (100.0) |
| Total         | 502/502 (100.0) | 502/502 (100.0) | 502/502 (100.0) | 502/502 (100.0) | 502/502 (100.0) |

IgG+: IgG seropositivity; IgG-: IgG seronegativity; IgM+: IgM seropositivity; IgM-: IgM seronegativity; *P <0.05

Table 2: prevalence of anti-T. gondii IgG and IgM antibodies seropositivity according to the sex of the studied babies

| Sex   | N  | IgG seropositivity no (%)          | IgM seropositivity no (%)          |
|-------|----|-----------------------------------|-----------------------------------|
| Boys  | 269| 49/269 (18.22%)* [49/502 (9.76%)]*| 2/269 (0.74%) [2/502 (0.4%)]      |
| Girls | 233| 41/233 (17.60%)* [41/502 (8.17%)]*| 1/233 (0.43%) [1/502 (0.2%)]      |
| Total | 502| 90/502 (17.93%)*                  | 3/502 (0.6%)                      |

*P <0.05 IgG+ vs IgM+
Table 3: Prevalence of anti-*T. gondii* IgG and IgM antibodies seropositivity according to the ages of the studied babies

| Age group (months) | IgG seropositivity no (%) | IgM seropositivity no (%) |
|-------------------|---------------------------|---------------------------|
| 0-6               | 36/502 (7.17)*            | 0/502 (0.0)               |
| 7-12              | 27/502 (5.38)*            | 0/502 (0.0)               |
| 13-18             | 25/502 (4.98)*            | 3/502 (0.6)*              |
| 19-24             | 2/502 (0.40)*             | 0/502 (0.0)               |
| 26-30             | 0/502 (0.0)               | 0/502 (0.0)               |
| 31-36             | 0/502 (0.0)               | 0/502 (0.0)               |
| 37-42             | 0/502 (0.0)               | 0/502 (0.0)               |
| 43-48             | 0/502 (0.0)               | 0/502 (0.0)               |
| Total             | 90/502 (17.93)*           | 3/502 (0.6)               |

*P < 0.05